Market Size
Respiratory Infectious Disease Diagnostics Market size was valued US$ 68.6 billion in 2025 and is estimated to reach US$ 79.2 billion by 2033, growing at a CAGR of 1.8% during the forecast period (2026-2033).
Respiratory Infectious Disease Diagnostics Market Statistics
Metrics | Details |
| Market CAGR | 1.8% |
| Segments Covered | By Disease Type, By Test Type, By End-User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
Get a free sample click here
Respiratory infections are caused by virus, bacteria, and other microbes, which further infect the respiratory system including the lungs, throat, and airways. Spread of infections is often through mucus and saliva that is usually expelled when the person sneezes, coughs, or laughs. Few of the germs are also spread though droplets that spread through air and also spread through travelling, which causes respiratory infections. Furthermore, some people can be infected by touching the remaining microbes on the surface, or touching contaminated hands.
Market Dynamics
The market is driven is the rising burden of respiratory diseases and technological advancements in the products.
Rising burden of respiratory diseases and technological advancements in the products are expected to drive market growth
Chronic obstructive pulmonary disease is a progressive lung disorder which causes reduction in airflow. According to the World Health Organization, 90% of the COPD deaths occur in low- and middle-income countries. Approximately 251 million cases of COPD were reported globally as per the study of the Global Burden of Disease Study. It is expected to increase in the coming years due to increasing aging population and changing lifestyle of people. Therefore, early diagnosis and treatment is very important which is expected to boost the market growth.
Rapid rise in burden of chronic obstructive pulmonary disorders such as chronic bronchitis, emphysema, asthma, and other lung diseases such as tuberculosis, pneumonia, is estimated to boost the respiratory infectious disease diagnostics market. Furthermore, rising lower respiratory infectious disease drives the need for early detection, which further drivers the demand for diagnostics tests. This factor will drive the growth of market in the forecast period.
Stringent regulatory framework coupled with unfavorable reimbursement policies are one of the major factors hindering the growth of the market
However, a stringent regulatory framework coupled with unfavorable reimbursement policies and a low awareness rate among the patient population will hamper the growth of the market in the forecast period.
Industry Analysis
The global respiratory infectious disease diagnostics market provides in-depth analysis of the market based on various industry factors such as porter’s five forces, regulatory analysis, reimbursement analysis, supply chain analysis, pricing analysis, technological advancements etc.
Segment Analysis
Coronavirus infections segment is expected to hold the largest market share in global blood pressure monitoring devices market
People with existing illnesses such as cardiovascular disease, chronic respiratory disease, hypertension, and diabetes are expected to experience a higher than average fatality rate. Moreover, according to the Chinese CDC, males are more vulnerable to becoming severely ill with the virus than women. The male fatality rate is 2.8% and the female fatality rate is 1.7%. This factor will drive the growth of market in the forecast period.
Geographical Presentation
North America dominated the global respiratory infectious disease diagnostics market and is expected to grow at the highest CAGR during the forecast period due to growing burden of respiratory diseases and higher prevalence of smoking.
Adoption of rapid diagnostics tests for faster diagnosis of respiratory infectious diseases is another key factor that is anticipated to augment the respiratory infectious disease diagnostics market in the region. As per CDC statistics, in May 2020, the Real-Time Reverse Transcriptase (RT)-PCR Diagnostic Panel is efficient in detecting the SARS-CoV-2 virus in respiratory specimens. The USFDA also offered its Emergency Use Authorization (EUA) for this test in February 2020. These factors are expected to drive the growth of market in the forecast period.
Competitive Landscape
The global respiratory infectious disease diagnostics market is highly competitive with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition Abbott Laboratories, Thermo Fisher Scientific Inc., Alere, Inc., Koninklijke Philips N.V., Cardinal Health, COSMED, Smiths Group plc, NIHON KOHDEN CORPORATION, Becton, Dickinson and Company, and F. Hoffmann-La Roche AG. are the leading market players with significant market share. The major players are using product development, novel product launches, market expansion, and product diversification strategies for holding their position in the market.
Recent Development-
- April 2025: F. Hoffmann-La Roche Ltd expanded its Cobas respiratory test menu globally, introducing advanced multiplex PCR panels capable of detecting a broader range of viral and bacterial pathogens, supporting syndromic testing strategies.
- March 2025: QIAGEN advanced its QIAstat-Dx respiratory panel portfolio with improved cartridge-based testing solutions, focusing on decentralized diagnostics and faster clinical decision-making in Europe and Asia-Pacific markets.
- March 2025: Abbott Laboratories expanded its rapid respiratory testing portfolio by enhancing multiplex molecular diagnostics on its ID NOW and Alinity platforms, enabling faster detection of influenza, RSV, and COVID-19 in point-of-care settings across U.S. hospitals and clinics.
- February 2025: Thermo Fisher Scientific introduced upgraded PCR-based respiratory panels under its Applied Biosystems brand, focusing on high-throughput laboratory workflows and improved sensitivity for co-infection detection during peak respiratory seasons.
The global respiratory infectious disease diagnostics market report will provide access to approximately 45+market data table, 40+figures and 180pages.
